The Persistence of Specific Immunoglobulin A Against SARS-CoV-2 in Human Milk After Maternal COVID-19 Vaccination
Objectives: To investigate SARS-CoV-2 specific immunoglobulin A (sIgA) in breast milk of Thai mothers post COVID-19 vaccination and/or SARS-CoV-2 infection, and to compare the sIgA among lactating mothers with varying COVID-19 vaccination regimes. Materials and Methods: A longitudinal study was conducted in lactating mothers receiving ≥2 doses of COVID-19 vaccine or confirming SARS-CoV-2-positive test as a part of an infant feeding survey. Vaccination and infection details were collected through questionnaires and interviews. Self-collected breast milk samples (30 mL) at 1, 3, and 6 months postvaccination or infection were analyzed for sIgA through enzyme-linked immunosorbent assay (ELISA). Results: Eighty-eight lactating mothers (152 milk samples), average age of 30.7 ± 6.2 years, were recruited. Fifty-five percent of milk samples were from lactating mothers with both SARS-CoV-2 infection and vaccination (hybrid immunity); 40% were from those with vaccination alone (COVID naïve). Sixty percent of lactating mothers received mixed types of vaccines. Median sIgA ratio in breast milk was 2.67 (0.82-7.85). Breast milk sIgA at 1, 3, and 6 months were higher in mothers with hybrid immunity than in COVID naïve (geometric mean [95% confidence interval]: 3.30 [2.06-5.29] versus 1.04 [0.52-2.04], 3.39 [2.24-5.13] versus 1.26 [0.77-2.06], 4.29 [3.04-6.06] versus 1.33 [0.74-2.42], respectively). No significant differences were observed among various vaccination regimes. Conclusion: sIgA against SARS-CoV-2 was detected in breast milk for up to 6 months after immunization together with infection at a greater level than after immunization or infection alone. This immunity could be transferred and protective against SARS-CoV-2 infection. Discontinuation of breastfeeding among mothers who received COVID vaccination or experienced infection should be discouraged. Clinical Trial Registration number: TCTR20220215012.
| Errataetall: |
ErratumIn: Breastfeed Med. 2024 Jan;19(1):69. - PMID 38241133 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine - 18(2023), 12 vom: 14. Dez., Seite 943-950 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Suteerojntrakool, Orapa [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Breast milk |
|---|
| Anmerkungen: |
Date Completed 18.12.2023 Date Revised 08.03.2024 published: Print ErratumIn: Breastfeed Med. 2024 Jan;19(1):69. - PMID 38241133 Citation Status MEDLINE |
|---|
| doi: |
10.1089/bfm.2023.0210 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365911437 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365911437 | ||
| 003 | DE-627 | ||
| 005 | 20240309232045.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1089/bfm.2023.0210 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1321.xml |
| 035 | |a (DE-627)NLM365911437 | ||
| 035 | |a (NLM)38100444 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Suteerojntrakool, Orapa |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Persistence of Specific Immunoglobulin A Against SARS-CoV-2 in Human Milk After Maternal COVID-19 Vaccination |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.12.2023 | ||
| 500 | |a Date Revised 08.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a ErratumIn: Breastfeed Med. 2024 Jan;19(1):69. - PMID 38241133 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Objectives: To investigate SARS-CoV-2 specific immunoglobulin A (sIgA) in breast milk of Thai mothers post COVID-19 vaccination and/or SARS-CoV-2 infection, and to compare the sIgA among lactating mothers with varying COVID-19 vaccination regimes. Materials and Methods: A longitudinal study was conducted in lactating mothers receiving ≥2 doses of COVID-19 vaccine or confirming SARS-CoV-2-positive test as a part of an infant feeding survey. Vaccination and infection details were collected through questionnaires and interviews. Self-collected breast milk samples (30 mL) at 1, 3, and 6 months postvaccination or infection were analyzed for sIgA through enzyme-linked immunosorbent assay (ELISA). Results: Eighty-eight lactating mothers (152 milk samples), average age of 30.7 ± 6.2 years, were recruited. Fifty-five percent of milk samples were from lactating mothers with both SARS-CoV-2 infection and vaccination (hybrid immunity); 40% were from those with vaccination alone (COVID naïve). Sixty percent of lactating mothers received mixed types of vaccines. Median sIgA ratio in breast milk was 2.67 (0.82-7.85). Breast milk sIgA at 1, 3, and 6 months were higher in mothers with hybrid immunity than in COVID naïve (geometric mean [95% confidence interval]: 3.30 [2.06-5.29] versus 1.04 [0.52-2.04], 3.39 [2.24-5.13] versus 1.26 [0.77-2.06], 4.29 [3.04-6.06] versus 1.33 [0.74-2.42], respectively). No significant differences were observed among various vaccination regimes. Conclusion: sIgA against SARS-CoV-2 was detected in breast milk for up to 6 months after immunization together with infection at a greater level than after immunization or infection alone. This immunity could be transferred and protective against SARS-CoV-2 infection. Discontinuation of breastfeeding among mothers who received COVID vaccination or experienced infection should be discouraged. Clinical Trial Registration number: TCTR20220215012 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a breast milk | |
| 650 | 4 | |a breastfeeding | |
| 650 | 4 | |a lactating mothers | |
| 650 | 4 | |a specific IgA | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Immunoglobulin A |2 NLM | |
| 650 | 7 | |a Immunoglobulin A, Secretory |2 NLM | |
| 700 | 1 | |a Mekangkul, Eakkarin |e verfasserin |4 aut | |
| 700 | 1 | |a Ananta, Pattaraporn |e verfasserin |4 aut | |
| 700 | 1 | |a Maitreechit, Duangporn |e verfasserin |4 aut | |
| 700 | 1 | |a Khabuan, Siriporn |e verfasserin |4 aut | |
| 700 | 1 | |a Sodsai, Pimpayao |e verfasserin |4 aut | |
| 700 | 1 | |a Hirankarn, Nattiya |e verfasserin |4 aut | |
| 700 | 1 | |a Thumbovorn, Rungtip |e verfasserin |4 aut | |
| 700 | 1 | |a Chomtho, Sirinuch |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine |d 2006 |g 18(2023), 12 vom: 14. Dez., Seite 943-950 |w (DE-627)NLM171765958 |x 1556-8342 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2023 |g number:12 |g day:14 |g month:12 |g pages:943-950 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1089/bfm.2023.0210 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2023 |e 12 |b 14 |c 12 |h 943-950 | ||